(NASDAQ: IKNA) Ikena Oncology's forecast annual revenue growth rate of 269.83% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Ikena Oncology's revenue in 2025 is $659,000.On average, 1 Wall Street analysts forecast IKNA's revenue for 2027 to be $1,351,227,108, with the lowest IKNA revenue forecast at $1,351,227,108, and the highest IKNA revenue forecast at $1,351,227,108. On average, 1 Wall Street analysts forecast IKNA's revenue for 2028 to be $1,109,936,553, with the lowest IKNA revenue forecast at $1,109,936,553, and the highest IKNA revenue forecast at $1,109,936,553.
In 2029, IKNA is forecast to generate $2,798,970,438 in revenue, with the lowest revenue forecast at $2,798,970,438 and the highest revenue forecast at $2,798,970,438.